Review of TA169; Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma and TA178; Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma.

Proposal to move guidance to the static list

The revised date for review of the above guidance was June 2011. 

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal. 

All companies involved state that there is no significant new evidence to warrant a review at this time. Consequently, we propose that TA169 and TA178 should be transferred to the static list of technology appraisals.

Topics on the static list may be transferred back to the active list for further consideration if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance. 

Please see appendix A for a full list of the organisations we have contacted.